Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1992-11-17
1995-02-21
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514212, 514221, 514350, 514671, 514557, 514560, 514729, 514546, 514946, 514947, 514866, 514784, 514785, 514788, 514255, 424449, A61K 3155, A61K 3144, A61K 3122, A61K 970
Patent
active
053915488
ABSTRACT:
A transdermal flux enhancing pharmaceutical composition for transdermal administration to a human or lower animal subject comprising a safe and effective amount of a pharmacologically active compound or a prodrug thereof, an aqueous solvent system comprising from about 15 to 75% by volume of one or more water miscible solvents, and a penetration enhancer selected from certain 1-alkylazacycloheptan-2-ones and cis-olefin compounds of the formula
REFERENCES:
patent: 3591584 (1971-07-01), Lombardino
patent: 3669966 (1972-06-01), Ambrogi et al.
patent: 3892857 (1975-07-01), Difazio et al.
patent: 3989816 (1976-11-01), Rajadhyaksha
patent: 4102995 (1978-07-01), Hebborn
patent: 4126681 (1978-11-01), Reller
patent: 4188390 (1980-02-01), Campbell
patent: 4219548 (1980-08-01), Reller
patent: 4299826 (1981-11-01), Luedders
patent: 4309427 (1982-01-01), Lombardino
patent: 4316893 (1982-02-01), Rajadhyaksha
patent: 4405616 (1983-09-01), Rajadhyaksha
patent: 4444762 (1984-04-01), Rajadhyaksha
patent: 4537776 (1985-08-01), Cooper
patent: 4552872 (1985-11-01), Cooper et al.
patent: 4557934 (1985-12-01), Cooper
patent: 4563452 (1986-01-01), Esteve Soler
patent: 4572909 (1986-02-01), Campbell et al.
patent: 4626539 (1986-12-01), Aungst et al.
patent: 4654209 (1987-03-01), Leslie et al.
patent: 4755535 (1988-07-01), Minaskianian et al.
patent: 4863970 (1989-09-01), Patel et al.
patent: 4959365 (1990-09-01), Francoeur et al.
patent: 5023085 (1991-06-01), Francouer et al.
Stoughton, Enhanced Percutaneous Penetration with 1-Dodecylazacycloheptan-2-one, Arch Derm., 118, 474-477 (1982).
Cooper, Increased Skin Permeability for Lipophilic Molecules, J. Pharm. Sci., 73, 1153-1156 (1984).
Akhter et al., Penetration Enhancers in Human Skin-Effect of Oleic Acid and Azone on Flurbiprofen Permeation, J. Pharm. Pharmacol., 36, 7P (1984).
Patel et al., Comparative study of propylene glycol and caprylic/capric triglyceride vehicles for topical application, J. Soc. Cosmetic Chem., 36, 303-311 (1985).
Golden et al., Role of Stratum Corneum Lipid Fluidity in Transdermal Drug Flux, J. Pharm. Sci., 76, 25-28 (1987).
Priborsky et al., Combination Effect of Penetration Enhancers and Propylene Glycol on In Vitro Transdermal Absorption of Insulin, Drug Design & Delivery, 2, 91-97 (1987).
Cooper et al., Effect of Fatty Acids and Alcohols on the Penetration of Acyclovir Across Human Skin In Vitro, J. Pharm. Sci., 74, 688-689 (1985).
Bennett et al., Optimization of bioavailabiity of topical steroids: nonoccluded penetration enhancers under thermodynamic control, J. Pharm. Pharmacol. 37, 298-304 (1985).
Bennett et al., The Assessment of Some Potential Penetration Enhancers Using the Vasoconstrictor Test, J. Pharm. Pharmacol., 36, 8P (1984).
Bennett et al., Effectiveness of Skin Penetration Enhancers Propylene Glycol, Azone, Decylmethylsulphoxide and Oleic Acid with Model Polar (Mannitol) and Nonpolar (Hydrocortisone) Penetrants, J. Pharm. Pharmacol, 37, 84P (1985).
Hadgraft, J., et al., Facilitated Transport of Sodium Salicylate Across an Artificial Lipid Membrane by Azone, J. Pharm. Pharmacol., 37, 725-727 (1985).
Stoughton, R. B., et al., Azone.RTM.: A New Non-Toxic Enhancer of Cutaneous Penetration, Drug Development and Industrial Pharmacy, 9, 725-744 (1983).
Francoeur Michael L.
Potts Russell O.
Benson Gregg C.
Cintins Marianne M.
Criares T. J.
Pfizer Inc.
Richardson Peter C.
LandOfFree
Transdermal flux enhancing compositions to treat hypertension, d does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transdermal flux enhancing compositions to treat hypertension, d, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdermal flux enhancing compositions to treat hypertension, d will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1929889